Skip to content
OpenCapital
Get started

TScan Therapeutics, Inc. TCRX Q3 2025 earnings

Reported November 12, 2025 · Before market open

Revenue$2.5MBeat by $571.0K
EPS-$0.28Beat by $0.07
Revenue estimate$1.9M
EPS estimate-$0.35

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$1.9M
EPS estimate-$0.29

Versus estimates

Revenue

Q1 2026$982.0KMiss by $1.5MQ4 2025$2.6MBeat by $131.5K
Q3 2025$2.5MBeat by $571.0K
Q2 2025$3.1MBeat by $1.2MQ1 2025$2.2MBeat by $1.1MQ4 2024$665.0KMiss by $854.8K

Diluted EPS

Q1 2026-$0.22In lineQ4 2025-$0.18Beat by $0.09
Q3 2025-$0.28Beat by $0.07
Q2 2025-$0.28In lineQ1 2025-$0.26Beat by $0.02Q4 2024-$0.29Miss by $0.02

Ask the moment TScan Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did TScan Therapeutics, Inc. report Q3 2025 earnings?
TScan Therapeutics, Inc. (TCRX) reported Q3 2025 earnings on November 12, 2025 before market open.
What were TScan Therapeutics, Inc.'s Q3 2025 revenue and EPS?
TScan Therapeutics, Inc. reported revenue of $2.5M and eps of $-0.28 for Q3 2025.
Did TScan Therapeutics, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $1.9M by $571.0K. EPS beat the consensus estimate of $-0.35 by $0.07.
How did TScan Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 139.4% from $1.0M a year earlier and eps declined 12.0% from $-0.25.
Where can I find TScan Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-275889) and the 10-Q periodic report (0001193125-25-275933) directly on SEC EDGAR. The filing index links above go to sec.gov.